Latest News about psychedelics
Recent news which mentions psychedelics
Cybin Completes Dosing In Phase 2 Study Of CYB003 For Major Depressive Disorder Treatment
October 03, 2023
Tickers
CYBN
From Benzinga
From Benzinga
Insider's Look At Psychedelics Industry On Risk Management, Gray Market & Cannabis Industry
October 03, 2023
From Benzinga
GH Research's Psychedelic Drug Candidate For Depression Meets FDA: Clinical Program On Hold
October 02, 2023
Tickers
GHRS
From Benzinga
Gov Newsom Green Lights Medical Psychedelics If Rescheduled And New Marijuana Testing Rules
October 02, 2023
From Benzinga
Psychedelic Therapy Providers: Risk Management Perspective From A Cannabis Insurance Specialist
October 02, 2023
From Benzinga
Argentina's Nacho Bottinelli On Psychedelics In Latin America: 'Brazil Opened A Giant Portal To Me'
October 02, 2023
From Benzinga
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
October 02, 2023
From Benzinga
Psychedelics Reform Update: Massachusetts, Pennsylvania, Maine, California, Michigan, Minnesota, Indiana
September 30, 2023
From Benzinga
Analyzing Long-Term Negative Responses To Psychedelics: Researchers Release Study
September 28, 2023
From Benzinga
EXCLUSIVE - Canada Approves First Legal Medical Psilocybin Access: Veteran To Undergo Apex's Macrodose Therapy
September 27, 2023
From Benzinga
Cybin And Fluence Partner To Support EMBARK Training For Phase 3 CYB003 Trial For Depression
September 26, 2023
Tickers
CYBN
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.